Reviews/Polyphenols and Antioxidants/Flavonoids lower cardiovascular disease mortality
CV · POLY-CV-02 · v2
Borderline: within 4 points of the Likely/Uncertain boundary, so a re-grade could land either side.
People who eat more flavonoids, plant compounds in foods like tea, berries, apples and red wine, tend to die of heart disease less often than people who eat the least. This pattern appears in several very large groups followed for many years, including one of 369,827 older adults [3] and one of 56,048 Danes [9], and no study in this evidence set linked more flavonoids to more heart deaths. But all of these studies only track what people already eat; none assigned flavonoids in a trial, so they show a link rather than prove a cause. The link is also inconsistent: in several populations higher total flavonoid intake was tied to fewer deaths overall but not specifically to fewer heart deaths ([5], [6], [7]), and in one cohort only certain subtypes helped [11]. People who eat the most flavonoids also tend to have healthier diets and lifestyles overall [7], which could explain part of the apparent benefit. The panel read the evidence as a consistent association that stops short of a demonstrated cause.
Across the largest general-population cohorts, higher total flavonoid intake is associated with lower CVD mortality: top-versus-bottom quintile fatal-CVD RR 0.82 (95% CI 0.73, 0.92) in [1], all-CVD-death hazard ratios of 0.90-0.93 among 369,827 people in [3], and an inverse cardiovascular-mortality association plateauing near 500 mg/day in 56,048 participants in [9]; any-versus-no anthocyanidin intake gave a CVD RR of 0.91 (0.83, 0.99) in [2]. No included cohort reported a harmful association with CVD mortality. The direction is therefore consistent across independent populations and several flavonoid subclasses. Several included studies measured CVD-adjacent endpoints rather than death, namely CVD incidence [8], atherosclerotic-disease hospital admissions [17], and incident atherosclerosis [19]. The contested point: The division is on the exact endpoint: total flavonoids are tied to fewer CVD deaths in [1], [3] and [9] but are null for CVD mortality in [5], [6] and [7], where benefit appears only for all-cause mortality or for individual subclasses, and in [11] only flavanones and flavones reach borderline CVD-mortality significance. Whether the association reflects flavonoids themselves or an overall healthier diet and lifestyle is unresolved, since [7] reports its lowest-intake tertile had a worse metabolic pattern and less healthy lifestyle habits.
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Polyphenols and Antioxidants, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
All 14 included studies are observational prospective cohorts; no RCT exists in the corpus, so the causal verb 'lowers' exceeds what the designs can establish — only association is demonstrated.
Healthy-user/residual confounding is active: [7] reports the lowest-intake tertile 'showed a worse metabolic pattern and less healthy lifestyle habits,' so flavonoid intake proxies overall diet and lifestyle quality.
Where it remains uncertain. Total flavonoids are null for CVD mortality in [5], [6] and [7] (significant only for all-cause mortality or subclasses) and only borderline via flavanones/flavones in [11], and no RCT exists to exclude healthy-user confounding [7].
Aleatory
CVD-mortality estimates in smaller populations are imprecise, e.g. [5] CVD HR 0.77 with 95% CI 0.40-1.46 crossing 1.
Epistemic
[7] shows lowest-intake individuals had worse metabolic and lifestyle profiles, so intake proxies overall diet quality.
Inferential
No RCT exists in the corpus, so 'lowers' infers causation from an association the designs cannot establish.
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Primary direct support: large US cohort, total flavonoids, fatal CVD endpoint, significant inverse association.
“Men and women with total flavonoid intakes in the top (compared with the bottom) quintile had a lower risk of fatal CVD (RR: 0.82; 95% CI: 0.73, 0.92; P-trend = 0.01).”
Panel auditInternal validity: medium · scope of inference: Older US adults (mean age ~70) over 7 y of follow-up.Key limitations: single baseline FFQ · short follow-up · nonlinear associations · residual confounding
Supports subclass-level CVD-mortality reduction in postmenopausal women.
“significant inverse associations were observed between anthocyanidins and CHD, CVD, and total mortality [RR (95% CI) for any versus no intake: 0.88 (0.78, 0.99), 0.91 (0.83, 0.99), and 0.90 (0.86, 0.95)]”
Panel auditInternal validity: medium · scope of inference: Postmenopausal women in Iowa free of CVD at baseline.Key limitations: subclass-level not total-flavonoid estimate for CVD · single baseline FFQ · women only
Largest cohort (369,827); total flavonoids directly associated with lower CVD mortality.
“higher intakes of total flavonoids, flavonols, anthocyanidins, and flavones were consistently associated with lower risks of death from all CVDs (hazard ratios: 0.90-0.93)”
Panel auditInternal validity: medium · scope of inference: Older US adults (mean age 61) free of CVD, cancer, diabetes and ESRD at baseline.Key limitations: single baseline FFQ · residual confounding · observational
The composite CV-events endpoint bundles fatal and non-fatal events, so the direction for CVD mortality specifically is not determinable.
Panel auditInternal validity: medium · scope of inference: Spanish university graduates, mean age 37, relatively young and healthy.Key limitations: composite endpoint mixes fatal and non-fatal · borderline trend (P=0.09) · young educated sample
4 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent inverse association across the largest cohorts supports a Likely tier, held below Established by unresolved confounding and endpoint-specific heterogeneity in observational-only evidence.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No randomised evidence. The causal verb 'lowers' rests entirely on observational cohorts, so confounding cannot be excluded. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised controlled trial assigning a defined flavonoid intake with CVD mortality as a pre-specified endpoint.
Open question: Does increasing flavonoid intake causally reduce CVD mortality, or does the association reflect confounding? Why it is still open: All included studies are observational prospective cohorts with no RCT ([1], [3], [9], and others).
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19